Premium
A comparison of chlormezanone, meprobamate, and placebo
Author(s) -
Champlin F. B.,
Cotter C. F.,
Moskowitz M. D.,
Rossman M.,
Sheppard C.,
Merlis S.
Publication year - 1968
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt19689111
Subject(s) - meprobamate , placebo , medicine , anesthesia , placebo response , anxiety , depression (economics) , physical therapy , psychiatry , alternative medicine , pathology , economics , macroeconomics
A double‐blind, comparative survey was conducted on a combined sample of inpatients and outpatients presenting moderate degrees of anxiety, depression, somatic concern, and tension. Patients were randomly assigned to therapy. Twenty‐one patients received chlormezanone averaging 500 mg. (200 to 800 mg.) daily, for a maximum of 6 weeks. Twenty‐one patients were treated with an average of 500 mg. of meprobamate (400 to 600 mg.) daily. Twenty‐four patients were treated with an average of 3 placebo capsules (2 to 8) daily, for a maximum of 6 weeks. Ratings were conducted prior to and 2 weeks following medication, 6 weeks after the start of medication, and 2 weeks after medication stopped. Based upon the dual criteria of symptom reduction and frequency and intensity of untoward reactions, meprobamate was the more effective drug in this study.